Indication
Androgen-Resistant Prostatic Cancer
2 clinical trials
5 products
Product
Vobramitamab DuocarmazineClinical trial
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2027-05-01
Product
VobramitamabProduct
lorigerlimabProduct
docetaxelClinical trial
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-09-01
Product
Prednisone